Navigation Links
The Michael J. Fox Foundation Leads Charge to Develop Alpha-Synuclein PET Tracer to Image Parkinson's Disease Biomarker
Date:11/7/2013

NEW YORK, Nov. 7, 2013 /PRNewswire-USNewswire/ -- The pursuit of an imaging tool to visualize the protein alpha-synuclein, the hallmark pathology of Parkinson's disease (PD), in the brain is the subject of a paper published today in the Journal of Parkinson's Disease by three researchers from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The Foundation has assembled and leads a consortium to develop a radioactive PET tracer that could lead to better therapies and quality of life for Parkinson's patients.

"The time frame for developing a PET tracer can be a long one, on the order of several years, and requires some luck along the way. MJFF seeks to accelerate this process through a concerted effort to combine resources and expertise from several different groups," wrote the paper's authors.

Also today MJFF is hosting a workshop of industry and academic leaders investigating alpha-synuclein and other protein tracers to encourage support and collaboration around this goal.

"The ability to measure biomarkers of Parkinson's disease—including alpha-synuclein in the brain—would radically transform treatments for PD patients by allowing researchers to confirm diagnosis, stratify volunteers for clinical trials and measure drug efficacy faster," said Jamie Eberling, Ph.D., senior associate director of MJFF research programs and first author of the paper. "Availability of an alpha-synuclein tracer would be a huge leap forward for drug development."

Parkinson's disease is marked by clumps of alpha-synuclein, called Lewy bodies, in brain and body cells, which can currently only be measured at autopsy or inferred from protein levels in blood or cerebrospinal fluid. Scientists are hoping to develop a drug with a radioactive tag that can be read by positron emission tomography (PET) scans and that can bind to alpha-synuclein. With this tool, they could visualize the distribution of alpha-synuclein in the brain. Such tracking of these aggregates would help diagnose and track disease progression and monitor therapies targeted at reducing alpha-synuclein levels. As drugs targeting Lewy bodies move through development, researchers could test whether they change levels of alpha-synuclein rather than rely on a change in clinical symptoms, as they do now.

Development of a tracer of the protein beta-amyloid transformed Alzheimer's disease research, leading to insights on how that pathology leads to cognitive decline. PD researchers hope the ability to image alpha-synuclein could allow similar breakthroughs in not only Parkinson's disease, but also related parkinsonisms such as Lewy body dementia, multiple system atrophy and progressive supranuclear palsy.

In 2011 MJFF assembled a consortium with a contract research organization and two academic groups to collaborate on the pursuit of an alpha-synuclein tracer. To identify molecules that bind selectively and with high affinity for the protein, researchers screened 100,000 compounds selected through computational chemistry based on the alpha-synuclein structure. They have identified several promising compounds and continue to optimize them and radiolabel the most promising for further development.

"It is unfortunately a process of trial-and-error. While we're closing in on the compounds with the greatest likelihood of success, there are still hurdles to cross in the next phase of development," said Chester Mathis, Ph.D., director of the PET Facility at the University of Pittsburgh and a member of the MJFF Alpha-Synuclein Imaging Consortium.

The challenges this Parkinson's tracer faces are plenty. Alpha-synuclein is not very abundant in the brain, so the binding compound must be highly selective. Also, it accumulates intracellularly, so in addition to passing the blood-brain barrier, the selected molecule must also make it through the cell membrane. However, advancement to clinical testing of tracers for tau (another protein implicated in Alzheimer's that faces some of these same challenges) provides hope to researchers seeking an alpha-synuclein tracer.

At the workshop today, attendees share best practices and recommendations for next steps as the pursuit continues.

About The Michael J. Fox Foundation for Parkinson's Research

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers.  In addition to funding $375 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

For more information, visit us on Facebook, Twitter, Web and LinkedIn.


'/>"/>
SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Michael Feiz on What Makes a Great Bariatric Physician
2. Michael Walton Retires From The Female Health Company Board of Directors
3. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
4. Red Carpet Star Studded Celebrity Gala in Partnership with the Michael J. Fox Foundation for Parkinsons Research
5. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
6. Promising Parkinsons Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
7. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
8. Manhattan NYC Cosmetic Dentist Dr. Michael Wei Providing Invisalign Braces
9. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
10. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
11. Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):